Projects funded by the NCN
Bioconjugates of 103Pd nanostructures for targeted Auger electron therapy.
2022/45/B/ST5/01861
Keywords:
targeted therapy Auger electron emitter in-vivo generator
Descriptors:
- ST5_10: Functional materials/nanomaterials, nanoparticles
- ST4_18: Radiation and nuclear chemistry
- NZ7_14: Pharmacy, pharmacotherapy, pharmacology
Panel:
ST5 - Materials: materials synthesis, structure-properties relations, advanced and functional materials with designed properties, (macro)molecular architecture, material engineering
Host institution :
Instytut Chemii i Techniki Jądrowej
woj.
Principal investigator (from the host institution):
dr hab. Agnieszka Majkowska-Pilip
Number of co-investigators in the project: 5
Call: OPUS 23 - announced on 2022-03-28
Amount awarded: 1 228 400 PLN
Project start date (Y-m-d): 2023-02-02
Project end date (Y-m-d): 2026-02-01
Project duration:: 36 months (the same as in the proposal)
Project status: Pending project
Project description
Download the project description in a pdf file
Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
- Publication in academic press/journals (1)
- Au@109Pd core-shell nanoparticle conjugated to trastuzumab for the therapy of HER2+ cancers: studies on the applicability of 109Pd/109mAg in vivo generator in combined β- auger electron therapyAuthors:N. A. Gharibkandi, K. Wawrowicz, A. Majkowska‑Pilip, K. Żelechowska‑Matysiak, M. Wierzbicki and A. BilewiczAcademic press:EJNMMI Radiopharm Chem . (rok: 2023, tom: 8, strony: 26-42), Wydawca: Springer Nature Switzerland AGStatus:PublishedDOI:10.1186/s41181-023-00212-4 - link to the publication